"Bevacizumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-VEGF recombinant monoclonal antibody consisting of humanized murine antibody. It inhibits VEGF RECEPTORS and helps prevent the proliferation of blood vessels.
Descriptor ID |
D000068258
|
MeSH Number(s) |
D12.776.124.486.485.114.224.060.375 D12.776.124.790.651.114.224.060.438 D12.776.377.715.548.114.224.200.438
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Bevacizumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Bevacizumab [D12.776.124.486.485.114.224.060.375]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Bevacizumab [D12.776.124.790.651.114.224.060.438]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Bevacizumab [D12.776.377.715.548.114.224.200.438]
Below are MeSH descriptors whose meaning is more specific than "Bevacizumab".
This graph shows the total number of publications written about "Bevacizumab" by people in this website by year, and whether "Bevacizumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 0 | 2 | 2 |
2004 | 0 | 5 | 5 |
2005 | 0 | 4 | 4 |
2006 | 0 | 8 | 8 |
2007 | 0 | 15 | 15 |
2008 | 0 | 21 | 21 |
2009 | 0 | 23 | 23 |
2010 | 0 | 24 | 24 |
2011 | 0 | 35 | 35 |
2012 | 0 | 18 | 18 |
2013 | 0 | 29 | 29 |
2014 | 0 | 27 | 27 |
2015 | 6 | 17 | 23 |
2016 | 14 | 12 | 26 |
2017 | 8 | 11 | 19 |
2018 | 7 | 5 | 12 |
2019 | 4 | 13 | 17 |
2020 | 13 | 7 | 20 |
2021 | 6 | 9 | 15 |
2022 | 0 | 11 | 11 |
2023 | 0 | 17 | 17 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bevacizumab" by people in Profiles.
-
Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study. Oral Oncol. 2024 Apr; 151:106747.
-
The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab. J Neurooncol. 2024 Mar; 167(1):181-188.
-
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. Oncologist. 2023 Dec 11; 28(12):1100-e1292.
-
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer. Breast Cancer Res Treat. 2024 Feb; 204(1):123-132.
-
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study. Hepatol Commun. 2023 11 01; 7(11).
-
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 11 18; 402(10415):1835-1847.
-
Subthreshold Compared with Threshold Macular Photocoagulation for Diabetic Macular Edema: A Systematic Review and Meta-Analysis. Ophthalmol Retina. 2024 Mar; 8(3):223-233.
-
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer. Int J Gynecol Cancer. 2023 09 04; 33(9):1458-1463.
-
Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer. Autophagy. 2024 01; 20(1):114-130.
-
Unusual Initial Presentation of Hepatocellular Carcinoma as a Clavicular Head Mass. Oncology (Williston Park). 2023 08 08; 37(8):335-338.